Elotuzumab - CISMeF

Preferred Label : Elotuzumab;

NCIt synonyms : HuLuc63; Anti-CS1 Monoclonal Antibody HuLuc63;

NCIt definition : A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.;

Alternative definition : NCI-GLOSS: A monoclonal antibody being studied in the treatment of advanced multiple myeloma. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. HuLuc63 binds to CS1, a protein that is found mainly on the surface of multiple myeloma cells.;

UNII : 1351PE5UGS;

CAS number : 915296-00-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 915296-00-3 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Empliciti;

Molecule name : PDL-063; BMS-901608; HuLuc-63;

Codes from synonyms : CDR0000537332; 179;

Details

Origin ID

C66982;

UMLS CUI

C1832049;

Automatic exact mappings (from CISMeF team)
- HuLuc63 [MeSH concept]
CISMeF manual mappings
- Elotuzumab (substance) [SNOMED CT concept]
Currated CISMeF NLP mapping
- elotuzumab [MeSH concept]
- elotuzumab [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing elotuzumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Elotuzumab (substance) [SNOMED CT concept]
- Product containing elotuzumab (medicinal product) [SNOMED CT concept]
- elotuzumab [ATC Code]
- elotuzumab [MeSH Supplementary Concept]
- elotuzumab [MeSH concept]
Validated automatic mappings to BTNT
- elotuzumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Antibody-Dependent Cellular Cytotoxicity [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- SLAM Family Member 7 [NCIt concept]
is_component_of_chemotherapy_regimen
- Dexamethasone/Elotuzumab/Pomalidomide Regimen [NCIt concept]
- Elo-Rd Regimen [NCIt concept]
- Elo-Vd Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients